Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1128-1138

  Carrión Salip, Dolors ^a   Panosa, Clara ^a   Menendez, Javier A ^b   Puig, Teresa ^a   Oliveras, Glòria ^a   Pandiella, Atanasio ^c   De Llorens, Rafael ^a   Massaguer, Anna ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Epidermal growth factor receptor; Erlotinib; Human epidermal growth factor receptor 3; Neuregulin; Prostate cancer; Resistance

Indexed keywords

ANDROGEN; BETACELLULIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRASTUZUMAB;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANDROGENS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEUREGULIN-1; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER;

EID: 84865002334     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1509     Document Type: Article

References (70)

1. Zhu ML and Kyprianou N: Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 15: 841-849, 2008.
2. Pomerantz M and Kantoff P: Advances in the treatment of prostate cancer. Annu Rev Med 58: 205-220, 2007.
3. Traish AM and Morgentaler A: Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer 101: 1949-1956, 2009.
4. Shah RB, Ghosh D and Elder JT: Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 66: 1437-1444, 2006.
5. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
6. Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006.
7. Shi F, Telesco SE, Liu Y, Radhakrishnan R and Lemmon MA: ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 107: 7692-7697, 2010.
8. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ and Yarden Y: Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 271: 19029-19032, 1996.
9. Wilson KJ, Gilmore JL, Foley J, Lemmon MA and Riese DJ II: Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 122: 1-8, 2009.
10. Iwamoto R, Yamazaki S, Asakura M, et al: Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 100: 3221-3226, 2003.
11. Miyamoto S, Fukami T, Yagi H, Kuroki M and Yotsumoto F: Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res 29: 823-830, 2009.
12. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
13. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
14. Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21, 2003.
15. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
16. Baselga J: Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175-1178, 2006.
17. Bianco R, Troiani T, Tortora G and Ciardiello F: Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer 12 (Suppl 1): S159-S171, 2005.
18. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107: 1207-1218, 2006.
19. Benavente S, Huang S, Armstrong EA, et al: Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15: 1585-1592, 2009.
20. Di Lorenzo G, Tortora G, D'Armiento FP, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444, 2002.
21. Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285, 1999.
22. Soler M, Mancini F, Meca-Cortes O, et al: HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer 125: 2565-2575, 2009.
23. Ricciardelli C, Jackson MW, Choong CS, et al: Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 68: 830-838, 2008.
24. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A and Bologna M: Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 129: 165-174, 2003.
25. Dhupkar P, Dowling M, Cengel K and Chen B: Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells. Anticancer Res 30: 1905-1910, 2010.
26. Festuccia C, Gravina GL, Biordi L, et al: Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate 69: 1529-1537, 2009.
27. Canil CM, Moore MJ, Winquist E, et al: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-460, 2005.
28. Gravis G, Bladou F, Salem N, et al: Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 19: 1624-1628, 2008.
29. Wilding G, Soulie P, Trump D, Das-Gupta A and Small E: Results from a pilot phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 106: 1917-1924, 2006.
30. Ziada A, Barqawi A, Glode LM, et al: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332-337, 2004.
31. Whang YE, Armstrong AJ, Rathmell WK, et al: A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol: Mar 9, 2011 (Epub ahead of print).
32. Sridhar SS, Hotte SJ, Chin JL, et al: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 33: 609-613, 2010.
33. Nabhan C, Lestingi TM, Galvez A, et al: Erlotinib has moderate single-agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial. Urology 74: 665-671, 2009.
34. Yotsumoto F, Yagi H, Suzuki SO, et al: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561, 2008.
35. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20: 3-10, 2007.
36. Li C, Iida M, Dunn EF, Ghia AJ and Wheeler DL: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28: 3801-3813, 2009.
37. Ritter CA, Perez-Torres M, Rinehart C, et al: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919, 2007.
38. Hutcheson IR, Knowlden JM, Hiscox SE, et al: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 9: R50, 2007.
39. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ and Larijani B: HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 3: e2881, 2008.
40. Amin DN, Campbell MR and Moasser MM: The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 21: 944-950, 2010.
41. Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475, 2009.
42. Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441, 2007.
43. Mendelsohn J: Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother 52: 342-346, 2003.
44. Pinkas-Kramarski R, Lenferink AE, Bacus SS, et al: The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene 16: 1249-1258, 1998.
45. Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez E, Esparis-Ogando A and Pandiella A: Neuregulins and cancer. Clin Cancer Res 14: 3237-3241, 2008.
46. Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C and Parry G: EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122: 685-697, 2010.
47. Festuccia C, Angelucci A, Gravina GL, et al: Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 93: 964-975, 2005.
48. Viloria-Petit AM and Kerbel RS: Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 58: 914-926, 2004.
49. Koutsopoulos AV, Mavroudis D, Dambaki KI, et al: Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer 57: 193-200, 2007.
50. Onn A, Correa AM, Gilcrease M, et al: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10: 136-143, 2004.
51. Chow NH, Chan SH, Tzai TS, Ho CL and Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7: 1957-1962, 2001.
52. Wiseman SM, Makretsov N, Nielsen TO, et al: Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103: 1770-1777, 2005.
53. Brader S and Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 2-8, 2004.
54. Festuccia C, Muzi P, Millimaggi D, et al: Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer 12: 983-998, 2005.
55. Wang G, Reed E and Li QQ: Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med 14: 23-34, 2004.
56. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ and Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58: 2720-2723, 1998.
57. Zhu Z, Kleeff J, Friess H, et al: Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 273: 1019-1024, 2000.
58. Torring N, Jorgensen PE, Sorensen BS and Nexo E: Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 20: 91-95, 2000.
59. Torring N, Hansen FD, Sorensen BS, Orntoft TF and Nexo E: Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. Prostate 64: 1-8, 2005.
60. Gupta GP, Nguyen DX, Chiang AC, et al: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765-770, 2007.
61. Watanabe T, Kobunai T, Yamamoto Y, et al: Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer 46: 2119-2126, 2010.
62. Oliveras-Ferraros C, Vall-Llovera AM, Salip DC, et al: Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs 30: 846-852, 2012.
63. Baker JB, Dutta D, Watson D, et al: Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 104: 488-495, 2011.
64. Ben-Yosef R, Starr A, Karaush V, et al: ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate 67: 871-880, 2007.
65. Vexler A, Lidawi G, Loew V, et al: Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies. Cancer Biol Ther 7: 1090-1094, 2008.
66. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B and Bartlett JM: The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12: 123-130, 2006.
67. Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378, 2009.
68. De Alava E, Ocana A, Abad M, et al: Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 25: 2656-2663, 2007.
69. Motoyama AB, Hynes NE and Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151-3158, 2002.
70. Normanno N, De Luca A, Maiello MR, et al: The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207: 420-427, 2006.